Kitay-Cohen Y, Lishner M, Shelef A, Ravid M, Manor Y
Department of Hematology, Meir Hospital, Kfar Saba, Israel.
Leuk Lymphoma. 1996 Jan;20(3-4):333-6. doi: 10.3109/10428199609051627.
Intensive combination chemotherapy administered to patients with non-Hodgkin's lymphoma (NHL) is inevitably associated with neutropenia and fever. However, the subset of patients who are at increased risk for myelotoxicity has not been clearly identified as yet. We evaluated 58 patients with NHL in order to verify whether bone marrow involvement (BMI) at diagnosis is a risk factor for neutropenia and infection following intensive chemotherapy. Patients with bone marrow involvement had significantly lower neutrophil counts both at diagnosis and following chemotherapy. An higher percentage of patients with BMI developed neutropenia (< 1000/mm3) following chemotherapy. Furthermore events of febrile neutropenia were more frequently encountered in patients with BMI. We conclude that BMI in patients with NHL is a risk factor for chemotherapy induced neutropenia and fever. The role of colony stimulating factors, administered in an attempt to prevent this complication, should be explored.
对非霍奇金淋巴瘤（NHL）患者进行强化联合化疗不可避免地会导致中性粒细胞减少和发热。然而，骨髓毒性风险增加的患者亚组尚未被明确识别。我们评估了58例NHL患者，以验证诊断时的骨髓受累（BMI）是否是强化化疗后中性粒细胞减少和感染的危险因素。骨髓受累患者在诊断时和化疗后的中性粒细胞计数均显著降低。化疗后BMI患者发生中性粒细胞减少（<1000/mm3）的比例更高。此外，BMI患者更频繁地出现发热性中性粒细胞减少事件。我们得出结论，NHL患者的BMI是化疗诱导的中性粒细胞减少和发热的危险因素。应探索集落刺激因子在预防这种并发症方面的作用。
